CA-VELO3D
11.3.2021 15:17:03 CET | Business Wire | Press release
VELO3D is pleased to announce that Chromalloy , a manufacturing and repair solutions provider for gas turbine engine manufacturers and operators worldwide, recently selected the VELO3D Sapphire® system as their additive manufacturing (AM) solution to significantly impact the economics of future Maintenance, Repair & Operations (MRO) projects in Chromalloy’s aviation and energy markets.
Chromalloy is installing the VELO3D Sapphire® in its manufacturing and repair services environment. This industrial AM technology is increasingly being adopted by manufacturers as a solution to offset the high costs of low-volume, direct-part replacement for conventionally produced parts when demand and long-term forecasting are uncertain.
“Chromalloy continues to seek innovative alternatives for our customers to extend the life of their engines and reduce their MRO costs,” says John Green, Vice President, Engineering & Technology, Chromalloy. “The VELO3D additive manufacturing equipment provides a unique, practical solution for our proprietary LifeX customer solutions.”
According to Chromalloy’s Jim Whitton, Director, Innovation Strategy, “For Chromalloy, 3D printed parts must provide inherent value because they are 3D printed. Otherwise, the printing itself is just a novelty. VELO3D’ s unique build capability and material density create high value by reducing post-processing requirements.”
VELO3D will qualify Chromalloy’s machine for 3D printing nickel-based superalloys, including Hastelloy® X, which is known for its strength and durability characteristics in high temperature environments. VELO3D is renowned for enabling geometric freedom through its patented SupportFree process. The capability to produce practically unlimited geometries eliminates the need to redesign legacy parts in order to produce them with AM. This tremendously reduces the barrier of transitioning legacy parts, produced historically by casting, welding or brazing, to additive manufacturing.
All Sapphire machines come standard with VELO3D ‘s highly automated, user-friendly Flow™ pre-print software and Assure™ quality assurance and control system.
“As an industry leader in the aviation MRO space, Chromalloy is an excellent partner for us,” says Benny Buller, VELO3D founder and CEO. “They have the expertise to open up a whole market category of parts. With the flexibility to produce high value, high mix, low-volume parts, AM allows the supply chain to be scaled to market- and customer-specific requirements.”
Jim Whitton agrees. “For complex gas turbine combustor components that have limited aftermarket availability or high replacement cost, the Sapphire system will allow Chromalloy to produce hardware on-demand, negating high NPI (new product introduction) tooling costs and lead-times of other methods,” he says.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005048/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
